Argenta Discovery Ltd. has announced that it has entered into two-year drug discovery collaboration with Genentech, Inc.
Under the terms of the agreement, scientists from the two companies will exploit Argenta’s expertise in computer-aided drug design (CADD), medicinal chemistry, biology and ADME/PK to discover chemical entities acting against an undisclosed drug target defined by Genentech.
Commenting on the agreement, Dr Christopher Ashton, Argenta’s CEO, said, "We are delighted that Genentech has chosen to work with Argenta on this important programme."
"This is our first collaboration with the company and we believe its decision to work with Argenta is a tribute to the skills of our 90-strong drug discovery team."
"It is gratifying that Argenta’s determination to refine and broaden its integrated drug discovery capabilities should be rewarded with high calibre collaborations of this kind."
"Our objective is to secure and retain more high quality, long-term collaborations with leading pharmaceutical and biotechnology companies and today’s announcement is another step towards realising that objective."
Dr Ashton further aided, "We look forward to building a long and successful relationship with Genentech."